Gabriel Precision Oncology

Gabriel Precision Oncology Limited was established in 2020 to make precision oncology a reality for all cancer patients. Gabriel is founded on a deep understanding of the entire clinical cancer pathway, including diagnostics, stratification, standard of care therapy and experimental treatment approaches. Through their combined experience, gleaned from leaderships roles in healthcare delivery, academic research and commercial drug development, the Gabriel team are focussed on democratising access to genomic analysis for cancer patients to maximise the benefits of current therapies and expedite the development of novel therapeutic approaches. Gabriel is exciting to be working with Congenica to make precision medicine a reality for those living with cancer.